<DOC>
	<DOCNO>NCT02065154</DOCNO>
	<brief_summary>The main purpose study assess effect cyclophosphamide ( cytoxan ) post transplant set prevent onset acute graft-versus-host disease ( GVHD ) . The primary objective determine incidence grade II-IV acute GVHD follow Allogeneic ( allo ) Hematopoeitic Cell Transplant ( HCT ) use post-transplant cyclophosphamide ( cytoxan ) patient human leukocyte antigen ( HLA ) match unrelated ( MUD ) mismatch unrelated ( MMUD ) donor . Other objective study determination disease-free survival ( DFS ) overall survival ( OS ) follow allo HCT ass safety post-transplant cyclophosphamide ( cytoxan ) MUD MMUD transplantation . Disease recurrence time recurrence patient receive post-transplant cyclophosphamide compare historical control without post-transplant cyclophosphamide ( cytoxan ) also evaluate . Other objective determine time onset , severity , responsiveness treatment , organ involve acute chronic GVHD well observation Immune Reconstitution time .</brief_summary>
	<brief_title>Post Transplant Cyclophosphamide ( Cytoxan ) GvHD Prophylaxis</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Disease Criteria : patient must meet diagnostic criterion acute myeloid leukemia ( AML ) , acute lymphoblastic leukemia ( ALL ) , chronic myeloid leukemia ( CML ) , chronic lymphocytic leukemia ( CLL ) , nonHodgkin lymphoma ( NHL ) , Hodgkin lymphoma ( HL ) , myelodysplastic syndrome ( MDS ) , myelofibrosis , severe aplastic anemia . Patients allow study deem eligible allo HCT regardless remission status . Age Criteria : 19 65 year age . Organ Function Criteria : All organ function test do within 28 day study registration . Cardiac : Left ventricular ejection fraction ( LVEF ) ≥ 50 % MUGA ( Multi Gated Acquisition ) scan echocardiogram . Pulmonary : FEV1 ( Forced expiratory volume 1 second ) FVC ( Forced vital capacity ) ≥ 50 % predict , DLCO ( diffuse capacity lung carbon monoxide ) ( correct hemoglobin ) ≥ 50 % predict . Renal : The estimated creatinine clearance ( CrCl ) must equal great 60 mL/min/1.73 m2 calculate CockcroftGault Formula : CrCl= ( 140age ) x weight ( kg ) x 0.85 ( female ) /72 x serum creatinine ( mg/dL ) Hepatic : Serum bilirubin 1.5 upper limit normal ( ULN ) Aspartate transaminase ( AST ) /alanine transaminase ( ALT ) 2.5 ULN Alkaline phosphatase 2.5 ULN Performance status : Karnofsky ≥ 70 % . , Patient must inform investigational nature study accordance institutional federal guideline ability provide write informed consent prior initiation studyrelated procedure , ability , opinion principal investigator , comply requirement study . Patient suitable willing HLA8/8 match 6/8 mismatch ( one allele ) unrelated donor identify . Noncompliant medication . No appropriate caregiver identify . HIV1 ( Human Immunodeficiency Virus1 ) HIV2 positive Uncontrolled medical psychiatric disorder . Uncontrolled infection , define positive blood culture within 72 hour study entry , evidence progressive infection image study chest CT scan within 14 day registration . Active central nervous system ( CNS ) leukemia . Preceding allogeneic HSCT . Pregnancy Breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>acute lymphoblastic leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>chronic myeloid leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>chronic lymphocytic leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>non-Hodgkin lymphoma</keyword>
	<keyword>NHL</keyword>
	<keyword>Hodgkin lymphoma</keyword>
	<keyword>HL</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>myelofibrosis</keyword>
	<keyword>severe aplastic anemia</keyword>
</DOC>